https://www.firstwordhealthtech.com/story/5570485 Remedee Labs announced Thursday that the FDA granted a breakthrough therapy device designation to its endorphin stimulator for patients with fibromyalgia. CEO David Crouzier called the achievement a "major step, one that recognises [the product's] potential for treating fibromyalgia patients' pain." The technology uses peripheral stimulation to trigger the release of endorphins, potentially offering fibromyalgia patients a non-pharmaceutical way of relieving symptoms such as pain, sleep disorders, fatigue and stiffness. According to Remedee's website, the solution is based on its Microelectronic Endorphin Trigger (MEET) module. By using low-energy, high-frequency electromagnetic waves, Remedee says the stimulator activates the body's peripheral sensitive nervous system to send a message to the brain to release endorphins.